Poseida Therapeutics to Present at Upcoming Investor Conferences
Poseida Therapeutics (Nasdaq: PSTX), a clinical-stage company focused on allogeneic cell therapy and genetic medicines, has announced its participation in two upcoming investor conferences in September 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Poseida Therapeutics (Nasdaq: PSTX), a clinical-stage company focused on allogeneic cell therapy and genetic medicines, has announced its participation in two upcoming investor conferences in September 2024. The company will engage in fireside chats at the H.C. Wainwright 26th Annual Global Investment Conference on September 9 at 10:30am ET and the 2024 Cantor Global Healthcare Conference on September 17 at 1:20pm ET.
These presentations offer investors an opportunity to gain insights into Poseida's progress in developing non-viral treatments for cancer and rare diseases. Live webcasts of both fireside chats will be accessible on Poseida's website, with replays available for approximately 90 days post-presentation.
Details
News Market Reaction – PSTX
The recorded move for PSTX in the trading session of this news was +3.62%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
H.C. Wainwright 26th Annual Global Investment Conference
Date: Monday, September 9, 2024
Time: 10:30am ET
2024 Cantor Global Healthcare Conference
Date: Tuesday, September 17, 2024
Time: 1:20pm ET
Live webcasts of the fireside chats will be available on the Investors & Media Section of Poseida's website, www.poseida.com. A replay of the webcast will be available for approximately 90 days following the presentation.
About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for both solid tumors and hematologic cancers as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients. Learn more at www.poseida.com and connect with Poseida on X and LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-upcoming-investor-conferences-302234400.html
SOURCE Poseida Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.